EUCTR2011-006176-39-IT进行中（未招募）不适用
Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter randomized Study of phase II - Protocol GOIM 21001
GOIM GRUPPO ONCOLOGICO MERIDIONALE0 个研究点开始时间: 2012年6月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •breast cancer HEr2 negative istologically confirmed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Bone metastasis as unic site of desease
- •Previous chemotherapy for metastatic desease or concomitant therapy with hormonal agents or byotherapy
- •Sintomatic cerebral metastasis
- •Hipertension non controlled
- •Psychic desease
- •Cardiac desease, ictus,transient ischemic attack, TIA
- •SNC desease
- •Ipersensibility to bevacizumab or to agents of protocol
研究者
相似试验
已完成
3 期
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaAIDS-related Kaposi SarcomaNCT00003350National Cancer Institute (NCI)240
进行中（未招募）
1 期
Panitumumab (Vectibix®) og liposomal doxorubicin (Caelyx®) til platinresistent epithelial ovariecancer uden KRAS mutationerPlatinresistent epithelial ovariecancer uden KRAS mutationer.MedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-007799-13-DKVejle Sygehus33
进行中（未招募）
不适用
Pegyliertes liposomales Doxorubicin versus Carboplatin / Paclitaxel bei Patientinnen mit Ovarialkarzinomrezidiv sechs bis zwölf Monate nach vorangegangener platinhal-tiger Chemotherapie: Änderung 2 Titel: eine Phase III internationale multizentrische randomisierte klinische Prüfung, die den Einfluss eines verlängerten platinfreien Intervalls auf das Überleben untersucht bei Patientinnen mit Ovarialkarzinomrezidiv sechs bis zwölf Monate nach vorangegangener platinhaltiger ChemotherapieEUCTR2008-001755-22-DEPhilipps-University Marburg250
进行中（未招募）
不适用
A randomized international study testing the effect of prolonging platinum patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy on survival.ovarian cancer recurrenceMedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001755-22-BEational Cancer Institute Naples, Italy250
已完成
2 期
Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II studyPatients with non-squamous non-small cell lung cancer who have failed previous treatmentsJPRN-UMIN000005608Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine Faculty of Medicine, Tottori University31